Apolipoprotein A-IV, a putative satiety/antiatherogenic factor, rises after gastric bypass

Obesity

Volumn 17, Issue 1, 2009, Pages 46-52

  Culnan, Derek M ^a   Cooney, Robert N ^a   Stanley, Bruce ^a   Lynch, Christopher J ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN A-IV; APOLIPOPROTEIN A4;

ARTICLE; BLOOD; BODY MASS; COMORBIDITY; FEMALE; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; MORBID OBESITY; PROTEOMICS; PSYCHOPHYSIOLOGY; REOPERATION; STATISTICS; STOMACH BYPASS; WEIGHT REDUCTION;

APOLIPOPROTEINS A; BODY MASS INDEX; COMORBIDITY; FEMALE; FOLLOW-UP STUDIES; GASTRIC BYPASS; HUMANS; MALE; MIDDLE AGED; OBESITY, MORBID; PROTEOMICS; REOPERATION; SATIETY RESPONSE; WEIGHT LOSS;

EID: 57949103001     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2008.428     Document Type: Article

References (51)

1. Miller K. Obesity: surgical options. Best Pract Res Clin Gastroenterol 2004;18:1147-1165.
2. Adams TD, Gress RE, Smith SC et al. Long-term mortality after gastric bypass surgery. N Engl J Med 2007;357:753-761.
3. Meneghini LF. Impact of bariatric surgery on type 2 diabetes. Cell Biochem Biophys 2007;48:97-102.
4. Bennett JC, Wang H, Schirmer BD, Northup CJ. Quality of life and resolution of co-morbidities in super-obese patients remaining morbidly obese after Roux-en-Y gastric bypass. Surg Obes Relat Dis 2007;3:387-391.
5. Dunkle-Blatter SE, St Jean MR, Whitehead C et al. Outcomes among elderly bariatric patients at a high-volume center. Surg Obes Relat Dis 2007;3: 163-169; discussion 9-70.
6. Monk JS Jr, Dia Nagib N, Stehr W. Pharmaceutical savings after gastric bypass surgery. Obes Surg 2004;14:13-15.
7. Torgerson JS. [The "Swedish Obese Subjects" (SOS) Study. What does weight loss really accomplish?]. MMW Fortschr Med 2002;144:24-26.
8. Sjostrom CD. Surgery as an intervention for obesity. Results from the Swedish obese subjects study. Growth Horm IGF Res 2003;13(Suppl A):S22-S26.
9. Brolin RE. Bariatric surgery and long-term control of morbid obesity. JAMA 2002;288:2793-2796.
10. Kendrick ML, Dakin GF. Surgical approaches to obesity. Mayo Clin Proc 2006;81:S18-S24.
11. Tichansky DS, Boughter JD Jr, Madan AK. Taste change after laparoscopic Roux-en-Y gastric bypass and laparoscopic adjustable gastric banding. Surg Obes Relat Dis 2006;2:440-444.
12. Pories WJ, Caro JF, Flickinger EG, Meelheim HD, Swanson MS. The control of diabetes mellitus (NIDDM) in the morbidly obese with the Greenville Gastric Bypass. Ann Surg 1987;206:316-323.
13. Korner J, Bessler M, Cirilo LJ et al. Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial concentrations of plasma ghrelin, peptide YY, and insulin. J Clin Endocrinol Metab 2005;90:359-365.
14. Cummings DE, Weigle DS, Frayo RS et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002;346:1623-1630.
15. Laferrere B, Heshka S, Wang K et al. Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care 2007;30:1709-1716.
16. Morinigo R, Moize V, Musri M et al. Glucagon-like peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 2006;91:1735-1740.
17. Qin X, Tso P. The role of apolipoprotein AIV on the control of food intake. Curr Drug Targets 2005;6:145-151.
18. Baralle M, Vergnes L, Muro AF et al. Regulation of the human apolipoprotein AIV gene expression in transgenic mice. FEBS Lett 1999;445:45-52.
19. Qin X, Swertfeger DK, Zheng S, Hui DY, Tso P. Apolipoprotein AIV: a potent endogenous inhibitor of lipid oxidation. Am J Physiol 1998;274:H1836-H1840.
20. Wong WM, Hawe E, Li LK et al. Apolipoprotein AIV gene variant S347 is associated with increased risk of coronary heart disease and lower plasma apolipoprotein AIV levels. Circ Res 2003;92:969-975.
21. Recalde D, Ostos MA, Badell E et al. Human apolipoprotein A-IV reduces secretion of proinflammatory cytokines and atherosclerotic effects of a chronic infection mimicked by lipopolysaccharide. Arteriosc Thromb Vasc Biol 2004;24:756-761.
22. Liang Y, Jiang XC, Liu R et al. Liver X receptors (LXRs) regulate apolipoprotein AIV-implications of the antiatherosclerotic effect of LXR agonists. Mol Endocrinol 2004;18:2000-2010.
23. Matthews DR, Hosker JP, Rudenski AS et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
24. Chen X, Sun L, Yu Y, Xue Y, Yang P. Amino acid-coded tagging approaches in quantitative proteomics. Exp Rev Proteomics 2007;4:25-37.
25. Barakat HA, Carpenter JW, McLendon VD et al. Influence of obesity, impaired glucose tolerance, and NIDDM on LDL structure and composition. Possible link between hyperinsulinemia and atherosclerosis. Diabetes 1990;39:1527-1533.
26. Gleysteen JJ, Barboriak JJ, Sasse EA. Sustained coronary-risk-factor reduction after gastric bypass for morbid obesity. Am J Clin Nutr 1990;51:774-778.
27. Gonen B, Halverson JD, Schonfeld G. Lipoprotein levels in morbidly obese patients with massive, surgically-induced weight loss. Metabolism 1983;32:492-496.
28. Bujalska IJ, Quinkler M, Tomlinson JW et al. Expression profiling of 11β-hydroxysteroid dehydrogenase type-1 and glucocorticoid-target genes in subcutaneous and omental human preadipocytes. J Mol Endocrinol 2006;37:327-340.
29. Xu S, Venge P. Lipocalins as biochemical markers of disease. Biochim Biophys Acta 2000;1482:298-307.
30. Rassart E, Bedirian A, Do Carmo S et al. Apolipoprotein D. Biochim Biophys Acta 2000;1482:185-198.
31. Vijayaraghavan S, Hitman GA, Kopelman PG. Apolipoprotein-D polymorphism: a genetic marker for obesity and hyperinsulinemia. J Clin Endocrinol Metab 1994;79:568-570.
32. Park JJ, Berggren JR, Hulver MW, Houmard JA, Hoffman EP. GRB14, GPD1, and GDF8 as potential network collaborators in weight loss-induced improvements in insulin action in human skeletal muscle. Physiol Genomics 2006;27:114-121.
33. Vanhollebeke B, Pays E. The function of apolipoproteins L. Cell Mol Life Sci 2006;63:1937-1944.
34. Tso P, Sun W, Liu M. Gastrointestinal satiety signals IV. Apolipoprotein A-IV. Am J Physiol Gastrointest Liver Physiol 2004;286:G885-G890.
35. Anonymous. APOA4 expression profiles 〈http://www.proteinatlas.org/ tissue-profile.php?antibody-id=2549#normal〉 (2008).
36. Kalogeris TJ, Qin X, Chey WY, Tso P. PYY stimulates synthesis and secretion of intestinal apolipoprotein AIV without affecting mRNA expression. Am J Physiol 1998;275:G668-G674.
37. Liu M, Doi T, Tso P. Regulation of intestinal and hypothalamic apolipoprotein A-IV. Exp Biol Med (Maywood) 2003;228:1181-1189.
38. Tso P, Liu M. Ingested fat and satiety. Physiol Behav 2004;81:275-287.
39. Lingenhel A, Eder C, Zwiauer K et al. Decrease of plasma apolipoprotein A-IV during weight reduction in obese adolescents on a low fat diet. Int J Obes Relat Metab Disord 2004;28:1509-1513.
40. Pessah M, Salvat C, Wang SR, Infante R. In vitro synthesis of apo-A-IV and apo-C by liver and intestinal mRNAs from lean and obese Zucker rats. Biochem Biophys Res Commun 1987;142:78-85.
41. Verges B, Guerci B, Durlach V et al. Increased plasma apoA-IV level is a marker of abnormal postprandial lipemia: a study in normoponderal and obese subjects. J Lipid Res 2001;42:2021-2029.
42. Fiegenbaum M, Hutz MH. Further evidence for the association between obesity-related traits and the apolipoprotein A-IV gene. Int J Obes Relat Metab Disord 2003;27:484-490.
43. Woods SC, D'Alessio DA, Tso P et al. Consumption of a high-fat diet alters the homeostatic regulation of energy balance. Physiol Behav 2004;83:573-578.
44. Fujimoto K, Machidori H, Iwakiri R et al. Effect of intravenous administration of apolipoprotein A-IV on patterns of feeding, drinking and ambulatory activity of rats. Brain Res 1993;608:233-237.
45. Lo CM, Zhang DM, Pearson K et al. Interaction of apolipoprotein AIV with cholecystokinin on the control of food intake. Am J Physiol Regul Integr Comp Physiol 2007;293:R1490-R1494.
46. Whited KL, Lu D, Tso P, Kent Lloyd KC, Raybould HE. Apolipoprotein A-IV is involved in detection of lipid in the rat intestine. J Physiol 2005;569: 949-958.
47. Weinstock PH, Bisgaier CL, Hayek T et al. Decreased HDL cholesterol levels but normal lipid absorption, growth, and feeding behavior in apolipoprotein A-IV knockout mice. J Lipid Res 1997;38:1782-1794.
48. Stein O, Stein Y, Lefevre M, Roheim PS. The role of apolipoprotein A-IV in reverse cholesterol transport studied with cultured cells and liposomes derived from an ether analog of phosphatidylcholine. Biochim Biophys Acta 1986;878:7-13.
49. Stein O, Stein Y. Atheroprotective mechanisms of HDL. Atherosclerosis 1999;144:285-301.
50. Dory L, Boquet LM, Hamilton RL, Sloop CH, Roheim PS. Heterogeneity of dog interstitial fluid (peripheral lymph) high density lipoproteins: implications for a role in reverse cholesterol transport. J Lipid Res 1985;26:519-527.
51. Kretowski A, Hokanson JE, McFann K et al. The apolipoprotein A-IV Gln360His polymorphism predicts progression of coronary artery calcification in patients with type 1 diabetes. Diabetologia 2006;49: 1946-1954.